CN1209128C - Traditional Chinese medicine composition with function of treating dysmenorrhea and beautifying - Google Patents
Traditional Chinese medicine composition with function of treating dysmenorrhea and beautifying Download PDFInfo
- Publication number
- CN1209128C CN1209128C CNB021165734A CN02116573A CN1209128C CN 1209128 C CN1209128 C CN 1209128C CN B021165734 A CNB021165734 A CN B021165734A CN 02116573 A CN02116573 A CN 02116573A CN 1209128 C CN1209128 C CN 1209128C
- Authority
- CN
- China
- Prior art keywords
- radix
- chinese medicine
- group
- medicine composition
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The present invention discloses a traditional Chinese medicine composition having the functions for treating dysmenorrhoea and beautifying the face, which is mainly prepared from angelica, chuanxiong rhizome, peach seed, safflower, tree peony bark, red sage root, prepared rehmannia root, bupleurum root, white paeony root, prepared nutgrass galingale rhizome, curcuma root, radix achyranthis bidentatae and radix polygoni multiflori preparata. The oral liquid proved by experiments has the functions for treating skin chloasma and age pigment and resisting wrinkles, and can treat diseases, such as irregular menstruation, dysmenorrhoea, etc.
Description
Technical field
The present invention relates to a kind of pharmaceutical preparation, particularly relate to a kind of Chinese medicine composition with treatment dysmenorrhea effect and beautification function.
Background technology
Dizziness, insomnia, hypochondriac pain, abdominal distention, menstruation color are dim, dark tongue quality, through diseases such as row pain, chloasma, be disease common on the gynecological clinic, the stagnation of liver-QI stasis is double sees the blood deficiency deficiency, is its common pathological mechanism the most.Chinese medicine is thought: the circulation of vim and vigour, regularly holding overflows is the basic of eumenorrhea.Song Zhao Ji cloud: " besides pure the moon of married woman is this with blood, is usefulness with gas, last be newborn the drink, infra is menses " (" Shengji Zonglu rolls up 151, married woman's vim and vigour door ").The woman is usefulness with blood, and sea of blood abundance is then active through water, and menstruation regularly hides and rush down, and the accent that also depends on irritability reaches, liver catharsis degree of having, then QI-blood circulation is normal, menses according to the time and go.On pathology, being invaded by exogenous pathogen, internal injury caused by excess of seven emotions, or blood-stasis internal-depression all can cause diseases such as disease warp, chloasma, but from clinical angle analysis, and the stagnation of liver-QI stasis blood deficiency deficiency of holding concurrently is its common pathogenesis." gynecological's statecraft menstruation door " cloud: " married woman is the sea with blood, and the married woman is from the people, and everything must not specially be gone; every angers of being worried more, and strongly fragrant gas is thought many ...; it is excessively then depressed to be worried, and depressed then blood is also tied ...; anger is QI rising in reverse order excessively then, and QI rising in reverse order then blood is also contrary, and the QI and blood knot is against in the internal organs meridians, then through as a result uncomfortable ", stagnation of QI blood agglomeration, hematogenous blockage; then be the trouble of dysmenorrhea, chloasma, the stagnation of QI is a hypochondriac pain then in two sides of body, amasss in abdomen then to be abdominal distention.Stagnation of QI blood stagnation with the passing of time, fresh blood is not given birth to, the blood deficiency deficiency is lost in moistening fosterly, " Rong Ze pain " more has blood deficiency not dive and holds back floating sun, then be the trouble of insomnia, clinical treatment is worked as with promoting blood circulation to remove obstruction in the collateral, soothing the liver nourishing blood to will.
Technology contents
The object of the invention is to provide a kind of Chinese medicine composition with treatment dysmenorrhea effect and beautification function (comprising treatment chloasma effect and crease-resistant effect).
The present invention seeks to be achieved through the following technical solutions:
Select Radix Angelicae Sinensis 35-105 weight portion, Rhizoma Chuanxiong 16-48 weight portion, Semen Persicae 10-30 weight portion, Flos Carthami 10-30 weight portion, Cortex Moutan 15-4 weight portion, Radix Salviae Miltiorrhizae 19-57 weight portion, Radix Rehmanniae Preparata 40-120 weight portion.
Wherein the weight proportion of each component can also be Radix Angelicae Sinensis 63-77 weight portion, Rhizoma Chuanxiong 29-33 weight portion, Semen Persicae 18-22 weight portion, Flos Carthami 18-22 weight portion, Cortex Moutan 27-33 weight portion, Radix Salviae Miltiorrhizae 34-42 weight portion, Radix Rehmanniae Preparata 77-93 weight portion.
In the said ratio most preferably proportioning be: Radix Angelicae Sinensis 70 weight portions, Rhizoma Chuanxiong 32 weight portions, Semen Persicae 20 weight portions, Flos Carthami 20 weight portions, Cortex Moutan 30 weight portions, Radix Salviae Miltiorrhizae 38 weight portions, Radix Rehmanniae Preparata 85 weight portions.
Above-mentioned composition of the present invention not only can blood circulation promoting and blood stasis dispelling, promoting tissue regeneration by removing blood stasis, and the kidney tonifying of can enriching blood, and all medicines are played the merit of nourishing blood and promoting blood circulation altogether.
On the basis of above-mentioned composition, also can add the medicine of promoting QI circulation for relieving depression such as Radix Bupleuri 13-38 weight portion, Radix Paeoniae Alba 9-27 weight portion, Rhizoma Cyperi (processed) 13-38 weight portion, Radix Curcumae 10-30 weight portion; Kidney tonifying medicine such as Radix Achyranthis Bidentatae 14-42 weight portion; Blood-nourishing medicine such as Radix Polygoni Multiflori Preparata 50-150 weight portion.
Wherein the drug weight proportioning of Zeng Jiaing can be: Radix Bupleuri 23-28 weight portion, Radix Paeoniae Alba 16-20 weight portion, Rhizoma Cyperi (processed) 23-28 weight portion, Radix Curcumae 18-22 weight portion, Radix Achyranthis Bidentatae 25-31 weight portion, Radix Polygoni Multiflori Preparata 86-104 weight portion.
The drug weight proportion optimization of above-mentioned increase is: Radix Bupleuri 25 weight portions, the Radix Paeoniae Alba 18 weight portions, Rhizoma Cyperi (processed) 25 weight portions, Radix Curcumae 20 weight portions, Radix Achyranthis Bidentatae 28 weight portions, Radix Polygoni Multiflori Preparata 95 weight portions.
The present invention can make any acceptable forms clinically according to following method.With common the decoction 2 times of above 13 flavors, add 3-6 times of water gaging the 1st time and boiled 1-3 hour, 1-3 times of water gaging of the 2nd adding boiled 1-2 hour, boiled and collected Aromatic water simultaneously, merge decocting liquid twice, leave standstill, centrifugal, concentrate, with Aromatic water, concentrated solution dosing together, dosing is left standstill, ultrafiltration or continue to concentrate, and drying is made any clinical acceptable forms.Also can relative density be reached more than 1.07 14% refined honey, Aromatic water, concentrated solution dosing together, regulate pH to 7.3～7.5 with NaOH, HCl weak solution; Left standstill 24 hours; Ultrafiltration, packing, 10ml/ props up, and every contains suitable crude drug amount is 5.06g.
Above-mentioned composition of the present invention can make QI-blood circulation and be beneficial to the fluent of menses, and the sea of blood is sufficient and make menses active, also can adjust taste if add Mel, and have the merit of coordinating the actions of various ingredients in a prescription concurrently.
Two kinds of compositionss of the present invention also can be made as any acceptable forms clinically such as tablet, oral liquid, pill, capsules according to a conventional method.
The oral liquid that the present invention makes confirms to have treatment skin chloasma and senile plaque and crease-resistant function, and can treat diseases such as menoxenia, dysmenorrhea through experimentation.
Oral liquid of the present invention can obviously be expanded Mice Auricle microcirculation venule, small artery bore, and velocity of blood flow is accelerated, and the blood capillary opening amount improves, and microcirculation improvement illustrates that this medicine improves peripheral tissues's nutrition, helps Pigmented elimination.Can obviously improve erythrocyte deformability, reduce whole blood viscosity, point out this medicine that function of promoting blood circulation to disperse blood clots is arranged, this also is one of factor of microcirculation improvement.Oral liquid of the present invention can obviously improve the SOD content in rat cerebral tissue and the blood, reduce MDA content simultaneously, but show this medicine delaying cell aging, increase the vigor of cerebral tissue and other tissue, and can obviously improve the Hb effect of mice, above-mentioned pharmacological action is an oral liquid nourishing the liver and kidney of the present invention, one of soothing the liver essence that nourishes blood.In addition, oral liquid of the present invention can obviously increase mouse anti-reflecting fatigue and anti-weary oxygen ability, illustrates that this medical instrument has anti-stress effect.Can obviously prolong nembutal length of one's sleep, showing has sedation, and oral liquid of the present invention has significant analgesia role, and its effect is held time similar to TIANQI TONGJING JIAONANG.”
Experimental example 1: the clinical effectiveness of oral liquid treatment skin chloasma of the present invention and senile plaque
Experimental technique
Oral liquid human clinical of the present invention tests and adopts controllable double-blind method evaluation, 24 weeks by a definite date.The skin expert is divided into two groups according to the feature of pigmented spots with the tester, pigmented spots group (M group) and senile plaque group (SL group).Through random assortment, about 2/3rds people takes oral liquid of the present invention in every group, and other people takes european plum dried meat juice (placebo group).Oral liquid of the present invention and placebo all leave in the vial of same label, and the tester takes four every day, early two, in two of evenings, withdraw 1 to 7 day of menstrual phase.The tester requires to avoid Exposure to Sunlight, uses the Neutrogena of SPF (sun protection factor) 15
RSuntan lotion.In 8 to 16 weeks, 16 experimenters are arranged because suntan lotion to the stimulation of skin, is used the Neurrogena of SPF (sun protection factor) 17 instead
RSuntan lotion (skin sensitivity type).In 24 all test processs, do not use other chemical products and related drugs.In experiment beginning and subsequent 2,4,8,12,16,20 and 24 weeks carried out clinical observation, take pictures and fill in the application form of testing oneself, all testers are before experiment and subsequent do blood test every month.Product Safety is according to whether producing system or the skin aspect untoward reaction, and seriousness is evaluated.
Tester's condition: must meet following standard:
The tester: the age 25 was to 60 years old healthy women, can be observed tangible pigmentation (black speck that is dispersed in, or the senile plaque of every side cheek more than two, darkness 3-5 level) by Wood light, be ready to accept all tests and instruct, finish every day and write down and the application form of testing oneself, agree follow-up investigation from now on.
The eliminator: participated in other clinical trial in the recent period, pregnancy, suckling, in nearly half a year the miscarriage history is arranged, facial skin disease (inflammation, eczema, psoriasis, lupus erythematosus, skin carcinoma etc.), the medicine of taking or taking in nearly 6 months steroid, similar effect comprises the Chinese medicine of other kind, taking or for oral administration be used for the cosmetics that a-hydroxy acid, salicylic acid, hydroquinone and use contain Chinese medicine in nearly 1 month, in 8 weeks of puerperal.
Have 98 people and participate in experiment.M organizes 46 people, age 30-55 year (mean age 42.0 ± 4.1); SL organizes 52 people, age 36-58 year (mean age 45.9 ± 5.5).
Assessment method
Clinical: Wood ultraviolet fluorescent lamp can improve the definition of facial colour spot, and the skin expert is divided into 0-6 rank with cutaneous pigmentation.0-does not have, and 1-is very shallow, and 2-is shallow, and 3-is medium, and 4-is darker, and 5-is dark, and 6-is very dark.The classification of skin fairness is to adopt identical stage division under visible light.The classification of mottle: 0-does not have speckle, the 1-minute quantity, and 2-is a small amount of, and 3-is more, and 4-is medium, and 5-is more serious, and 6-is very serious.
Image: every side surface part has the adaptive time of 30 fens kinds before taking, with digital camera taking under visible light and the ultraviolet fluorescent respectively.
Laboratory data: measure estradiol in the blood, progestogen, lutropin and the plain level of short follicle generation with radio immunoassay before and after the experiment.Blood before and after the determination experiment, urine composition.(blood: hematochrome, erythrocyte, leukocyte, platelet counts, urine: urine protein, erythrocyte, quantity of leucocyte)
Tester's self assessment: the tester will finish questionnaire in each investigation, and according to following standard test oneself skin splash, smoothness, pore size, skin flexibility, colour of skin situation: 1=is best, and 2=is good, and 3=is general, and 4=is poor.Untoward reaction has skin rubefaction, burning sensation, sensation of pricking, mottle increase, pimpling or other reaction, and according to following methods of marking record: 1=does not have, and 2=is slight, the 3=moderate, and 4=is serious.Menstrual cycle (normal, in advance, postpone), through blood volume (normal, a small amount of increase, increase a lot; The slight minimizing obviously reduces)
The result:
After 24 weeks, there are 96 to finish experiment among 98 testers, (1 people is of the present invention group of M to two people because the reason of non-product has withdrawed from experiment, because of causing the skin of face inflammation, sunscreen cream withdraws from test in 12 weeks, other 1 people is the M placebo group, abandon because of being reluctant to continue test), M and SL group are at equal zero differences in aspect such as age, occupation, go out the time (Exposure to Sunlight), mottle generation, product doses.
Clinical observation:
Chart list M group and SL group in the desalination pigmentation, increase the clinical scale appraisal result aspect three of the skin fairness, dispelling stain: (seeing Table 1)
Table 1:
Pigmentation N
0248 12 16 20 24
SL the present invention 35 4.00 ± 0.84 3.77 ± 0.94 3.51 ± 0.82 3.40 ± 0.85 3.17 ± 0.79 3.14 ± 0.88 3.40 ± 1.09 2.80 ± 0.96
SL placebo 17 3.53 ± 0.94 3.47 ± 0.94 3.06 ± 0.90 3.29 ± 0.77 3.12 ± 0.86 3.12 ± 0.93 3.18 ± 1.29 3.24 ± 0.83
M the present invention 29 4.03 ± 1.12 3.10 ± 0.90 2.97 ± 1.02 2.97 ± 0.82 2.62 ± 0.94 2.45 ± 0.99 2.76 ± 1.02 2.00 ± 0.93
M placebo 15 3.73 ± 0.96 3.27 ± 0.80 3.00 ± 1.13 2.93 ± 0.96 2.93 ± 0.88 3.20 ± 0.94 3.27 ± 0.88 2.93 ± 0.96
Skin fairness N
0248 12 16 20 24
SL the present invention 35 3.74 ± 0.82 3.06 ± 0.59 3.37 ± 0.69 3.17 ± 0.86 3.09 ± 0.74 2.91 ± 0.74 3.00 ± 0.87 2.86 ± 0.69
SL placebo 17 3.53 ± 0.87 3.12 ± 0.49 3.59 ± 0.62 3.06 ± 0.90 3.59 ± 0.62 2.71 ± 0.69 3.06 ± 0.66 3.18 ± 0.73
M the present invention 29 3.79 ± 0.90 2.93 ± 0.59 3.10 ± 0.62 3.10 ± 0.77 3.17 ± 0.76 2.69 ± 0.76 3.03 ± 0.98 2.76 ± 0.83
M placebo 15 3.87 ± 0.74 3.07 ± 0.46 3.13 ± 0.64 3.27 ± 0.80 3.20 ± 0.56 2.73 ± 0.59 3.33 ± 0.82 3.27 ± 0.59
Mottle N
0248 12 16 20 24
SL the present invention 35 3.34 ± 0.87 3.06 ± 0.84 2.71 ± 0.79 3.09 ± 0.74 2.71 ± 0.93 2.37 ± 0.94 2.86 ± 0.88 2.31 ± 0.80
SL placebo 17 3.29 ± 0.99 3.059 ± 0.66 2.71 ± 0.77 3.00 ± 0.79 3.00 ± 0.71 3.00 ± 0.71 3.12 ± 0.78 3.00 ± 0.79
M the present invention 29 3.86 ± 0.99 3.24 ± 0.83 3.28 ± 0.88 3.45 ± 0.78 3.28 ± 0.75 3.21 ± 0.77 3.28 ± 0.88 2.86 ± 0.74
M placebo 15 4.07 ± 0.70 3.27 ± 0.88 3.00 ± 0.76 3.60 ± 0.91 3.40 ± 0.83 3.40 ± 0.91 3.80 ± 0.86 3.33 ± 0.72
The clinical observation efficacy evaluation is summed up:
The desalination pigmentation:
-SL group: statistical result showed, of the present invention group of effect obviously is better than placebo group
-M group: statistical result obviously is better than matched group for of the present invention group, and effect continued more than 12 weeks
Increase the skin fairness:
-SL group: of the present invention group of statistical result curative effect occurs in 16 weeks, obviously is better than placebo group
-M group: do not change
Dispelling stain:
-SL group: statistical result showed, of the present invention group of curative effect obviously is better than placebo group
-M group: from the better effects if (P=0.12) of of the present invention group of chart
Experimenter's self-test result sums up
The desalination skin splash:
Of the present invention group of-SL is in 2-8 week and 24 weeks curative effect occurred
Of the present invention group of-M curative effects just occur in 24 weeks
Increase skin elasticity:
-SL effect occurs in 4-24 for of the present invention group
The effect that-M is of the present invention group only came across for 24 weeks
Pale and the hypopigmentation of skin:
-SLM does not find tangible curative effect for of the present invention group
Ruddy and the shrinking pore of the colour of skin:
M group better efficacy is a little.
Of the present invention group of SL: some testers curative effect occurs after taking for 8 weeks
Menstrual cycle and through blood volume no change (but of the present invention group of relieving dysmenorrhea, matched group does not have this effect) blood and urinalysis:
With blood before and after the experiment and the contrast of urine assay, at equal no changes in aspect such as hormonal readiness, cell compositions.
Digital picture is summed up:
Every group of captured digital photograph under special light condition (visible light and ultraviolet fluorescent) can be observed the variation of skin of face easily.96 testers under visible light, ultraviolet fluorescent lamp (both sides face, four testing time points) take 192 groups of photos altogether, and 3 every group, can arrange by both sides face and 4 time points, on computer-controlled monitoring instrument, carry out image grading.Shot picture is transferred to Clinical Research Center, by the skin expert the every comparison film (photo before and after the treatment) that occurs at random on the screen is carried out efficacy evaluation.Every group of curative effect assessment method statistic analysis of " T " check the results are shown in Table 2:
Table 2:
| Improvement situation score | The black speck group | |||||
| Product | Average classification | Statistical analysis | Improve | Zero difference | Variation | |
| Pigmentation | The present invention | 0.38 | P＝0.02 | 15 | 7 | 7 |
| Placebo | -0.33 | 6 | 2 | 7 | ||
| The skin fairness | The present invention | 0.03 | P＝0.59 | 8 | 14 | 7 |
| Placebo | -0.10 | 5 | 1 | 9 | ||
| Mottle | The present invention | 0.41 | P＝0.02 | 17 | 4 | 8 |
| Placebo | -0.20 | 6 | 1 | 8 | ||
| The senile plaque group | ||||||
| Pigmentation | The present invention | 0.31 | P＝0.65 | 16 | 12 | 7 |
| Placebo | 0.53 | 9 | 5 | 3 | ||
| The skin fairness | The present invention | 0.08 | P＝0.12 | 12 | 13 | 10 |
| Placebo | 0.00 | 5 | 7 | 5 | ||
| Mottle | The present invention | 0.30 | P＝0.95 | 19 | 6 | 10 |
| Placebo | 0.38 | 9 | 4 | 4 | ||
Draw oral liquid of the present invention to SL group desalination pigment and remove the speckle aspect and show tangible curative effect with the computerized image staging.
Conclusion:
1. oral liquid of the present invention has good toleration, has no side effect.
2. skin expert clinical observation can be desalinated senile plaque and skin splash after taking 12 weeks of the present invention.
3. dermatological clinical observation is taken 16 weeks of the present invention and 24 Zhou Houke and is alleviated senile plaque.
4. the skin expert observes, and SL group is improving whole body skin from different effects occurring aspect fair-skinned (gloss and brighten), and is only apparent in view in 12 curative effects all and 24 weeks.Of the present invention group of M group and placebo group notable difference occurring on 20 week back curative effects.
5. oral liquid of the present invention does not have functions of hormones, can not change menstrual cycle and blood, urine composition.
Experimental example 2: oral liquid treatment stagnation of liver-QI blood stasis of the present invention, or the clinical efficacy test of dysmenorrhea due to the double blood deficiency deficiency or dysmenorrhea merging chloasma.
One, physical data
Use oral liquid of the present invention and treat dysmenorrhea 110 examples (wherein dysmenorrhea merges chloasma person's 60 examples) minimal ages 16 years old, maximum 45 years old age, 29.9 years old mean age altogether; The course of disease is the shortest 1 month, the longest 20 years, average course of disease 5.2 years.
Two, case is selected
The traditional Chinese medical science or the Western medicine diagnose standard that meet dysmenorrhea and chloasma all can be used as the case selection.
Include standard in: 1, meet Chinese medical discrimination stagnation of liver-QI blood stasis or double syndrome of deficiency of blood person; 2, the dysmenorrhea that meets no organic disease, chloasma diagnosis person; 3, the age is more than 16 years old, person below 45 years old; 4, be ready to finish this experimenter.
Three, clinical implementation scheme:
(1), the treatment group is no less than 100 examples, matched group is no less than 50 examples.Above case is finished in 3 hospitals.
(2), random packet method:
Patient enters " health care oral liquid I of the present invention number group " or " health care oral liquid II of the present invention number group " according to the regulation on the identical card of extension set at random of sequence number successively by its prescription on individual diagnosis order.
(4) instructions about how to take medicine and dosage;
The treatment group is 10ml at every turn, and every day 3 times, 3 weeks of taking medicine continuously are a course of treatment.Dysmenorrhea patient begins to take medicine in 3 weeks before menstruation.
Four, criterion of therapeutical effect;
(1) dysmenorrhea curative effect determinate standard
Produce effects: integration is reduced to preceding more than 1/2nd of integration of treatment after treating, and stomachache obviously alleviates, all the other symptoms improvements (by +++→ ++ or ++ →+), the disobedience analgesic can be adhered to work.
Effectively: integration 1/3～1/2 stomachache alleviated before treatment back integration was reduced to treatment, and all the other symptoms take a turn for the better, and the clothes analgesic can be adhered to work.Invalid; Stomachache and all the other symptoms do not have the changer.
(2) chloasma efficacy assessment standard;
Produce effects: more than 50% of chloasma disappearance original area, all the other symptoms take a turn for the better,
Effectively: yellowish-brown rubbish color shoals thin out or all the other symptoms take a turn for the better.
Invalid: chloasma and other symptoms do not have change.
Five, therapeutic outcome
Table 3: the observation table of dysmenorrhea clinical efficacy (169 example)
Produce effects
Total routine number enabledisable total effective rate
Medicine example number X2
(n) the routine number of routine number (%) (%) (%)
(％)
Oral liquid 110 63 (57.3) 29 (26.4) 18 (16.3) 83.7 4.579 of the present invention
Shown in the table 3, oral liquid obvious effective rate of the present invention is 57.3%, and total effective rate is 83.7%.
Table 4: oral liquid treatment dysmenorrhea of the present invention merges the clinical efficacy statistical table (60 example) of chloasma in the chloasma
Total routine digital display is imitated the enabledisable total effective rate
(n) the routine number of the routine number of routine number (%) (%) (%) (%)
60 7(14) 41(66) 12(24) 80
Six, conclusion
The obvious effective rate of dysmenorrhea is that 57.3% total effective rate is 83.7% due to this test application oral liquid of the present invention (treatment group) treatment stagnation of liver-QI blood stasis or the double blood deficiency deficiency; It is 14% that treatment merges chloasma person's obvious effective rate, and total effective rate is 76%.The curative effect for the treatment of dysmenorrhea is better than WUJI BAIFENG KOUFUYE.
This test is at blood, routine urinalysis to carrying out before and after the 1/3 case treatment, liver, kidney function test, in, no abnormal change.The curative effect of oral liquid treatment dysmenorrhea of the present invention is definite, and nontoxic pair of effect, and is safe in utilization.
Experimental example 3: oral liquid of the present invention goes the observation of speckle, crease-resistant effect
Experimental technique:
Controllable double-blind method is adopted in this experiment, 24 weeks by a definite date, the skin expert is divided into two groups according to the feature of pigmented spots with the tester, chloasma group and senile plaque group, every group through random assortment, be divided into experimental group and the matched group Comparison of therapeutic of seeing off again, experimental group is taken oral liquid of the present invention, and matched group is taken fruit juice.The tester requires to avoid Exposure to Sunlight, before experiment and subsequent different times carry out clinical observation, digital picture and selftest.And before and after experiment, do the detection of aspects such as blood, urine, to observe the safety of oral liquid of the present invention.
Clinical observation result:
Oral liquid of the present invention is after taking for 12 weeks, and the mottle desalination alleviates, skin exquisiteness, gloss, the ruddy remarkable result of promptly seeing, and through 6 months clinical verification, curative effect was lasting.
Digital picture shows:
After taking oral liquid of the present invention, the chloasma area dwindles, and the pigmentation degree alleviates, skin smooth, ruddy; Senile plaque be improved significantly, decreased number, color alleviates, skin is taken preceding fine and smooth gloss, high resilience; Whole skin be improved significantly, more pale, be rich in gloss, have tangible whitening effect: wrinkle of skin obviously reduces, degree of depth wrinkle shoals, tiny wrinkle disappears.
Experimental example 4: oral liquid ferulaic acid content of the present invention is to the shadow of main pharmacodynamics
1, to hemorheological influence
Choose 50 of 180-200gSD ♀ rats, be divided into 5 groups at random, press 20ml/Kg body weight volume gastric infusion, matched group gavages the equivalent distilled water.Once a day, continuous 20 days.12 hours socket of the eye veins are got blood behind the last medicine, take into account LBY-Nn Trace Blood slurry viscosity instrumentation with the rotary blood viscosity of LBY-N6A type and decide whole blood viscosity (low cutting), whole blood viscosity (height is cut), capillary blood slurry viscosity, RBC hematocrit, whole blood reduced viscosity (low cutting), whole blood reduced viscosity (height is cut), RBC aggregate index, RBC deformation index, RBC electrophoresis index etc., press thrombocytometry and measure platelet count.Result of the test is done the t check.
2, to the influence of isolated uterine smooth muscle
Select 180 for use,-200gSD female rats, press isolated rat uterus laboratory method [2] clip uterus, with BL310 biological function experimental system record uterine contraction situation, after treating that uterine contraction is steadily, promptly give pituitrin modeling (spasticity), treat steadily after, promptly beginning administration (be 50% medicinal liquid), is index with difference before and after the administration.Experimental result is made t and is detected.
Result of the test
1. to hemorheological influence
Experimental result shows, the oral liquid of the present invention of 2000 high dose group can significantly reduce the capillary blood slurry viscosity and increase the RBC deformation index, compare with matched group, the oral liquid of the present invention of dosage group all decreases to whole blood viscosity (low cutting), whole blood viscosity (height is cut), capillary blood slurry viscosity, RBC hematocrit, whole blood reduced viscosity (low cutting), whole blood reduced viscosity (height is cut), RBC aggregate index, RBC deformation index, RBC electrophoresis index and platelet counts etc. in P＜0.05:2000 height, the middle dosage group and 9811, but P＞0.05.Show that each dosage group of oral liquid of the present invention all has the blood circulation promoting and blood stasis dispelling effect.
The table 5 couple hemorheological n:10 x ± SD that influences
Dosage whole blood viscosity (low cutting) whole blood viscosity (height is cut)
Group
(g/kg) (mPa.s) (％) (mPa.s) (％)
Distilled water 20ml 18.30 ± 4.70 6.13 ± 1.08
2000 high doses 4.08 16.20 ± 4.13 ↓ 11.50 5.61 ± 1.18 ↓ 8.50
Dosage 2.04 18.21 ± 5.40 ↓ 4.90 5.91 ± 0.97 ↓ 3.60 in 2000
Dosage 2.04 20.92 ± 2.74 ↑ 8.60 6.10 ± 0.54 ↓ 0.50 in 9811
Annotate: compare with matched group
*P＜0.05,
*P＜0.01, ↓ to represent to reduce, ↑ expression improves (down together)
The table 6 couple hemorheological n:10 x ± SD that influences
Dosage capillary blood slurry viscosity RBC hematocrit
Group (%)
(g/kg) (mPa.s) (％) (％)
Distilled water 20ml 13.6 ± 0.15 49.01 ± 3.75
2000 high doses, 4.08 1.19 ± 0.14* ↓ 12.60 44.61 ± 9.13 ↓ 9.10
Dosage 2.04 1.30 ± 0.13 ↓ 4.40 444.10 ± 5.09 ↓ 5.90 in 2000
Dosage 2.04 1.30 ± 0.12 ↓ 4.40 48.20 ± 3.82 ↓ 1.70 in 9811
The table 7 couple hemorheological n:10 x ± SD that influences
Dosage whole blood viscosity (low cutting) whole blood viscosity (height is cut)
Group
(g/kg) (mPa.s) (％) (mPa.s) (％)
Distilled water 20ml 36.01 ± 8.68 9.95 ± 1.70
2000 high doses 4.08 33.16 ± 5.24 ↓ 7.90 9.19 ± 1.00 ↓ 7.40
Dosage 2.04 34.14 ± 7.47 ↓ 5.20 9.91 ± 1.39 ↓ 0.40 in 2000
Dosage 2.04 36.30 ± 2.91 ↑ 0.80 9.88 ± 0.52 ↑ 0.70 in 9811
The table 8 couple hemorheological n:10 x ± SD that influences
Dosage
Group RBC aggregate index % RBC aggregate index %
(g/kg)
Distilled water 20ml 2.93 ± 0.31 0.930 ± 0.07
2000 high doses 4.08 2.61 ± 0.43 ↓ 10.90 1.16 ± 0.27
*↑ 24.9
Dosage 2.04 2.80 ± 0.32 ↓ 4.40 0.92 ± 0.04 ↓ 2.20 in 2000
Dosage 2.04 2.89 ± 0.35 ↓ 1.40 0.92 ± 0.05 ↓ 1.10 in 9811
Table 9 pair platelet counts influence n:10 x ± SD
The dosage platelet counts
Group RBC electrophoresis index % %
(g/kg) (×10
9/L)
Distilled water 20ml 5.94 ± 0.41 17.84 ± 10.68
2000 high doses 4.08 5.77 ± 0.42 ↓ 2.90 15.18 ± 4.97 ↓ 14.90
Dosage 2.04 5.88 ± 0.38 ↓ 1.00 15.78 ± 6.17 ↓ 11.55 in 2000
Dosage 2.04 5.90 ± 0.54 ↓ 0.70 15.94 ± 6.56 ↓ 10.65 in 9811
2, to the influence of isolated uterine smooth muscle
Experimental result shows: oral liquid of the present invention can significantly reduce the contraction frequency of the isolated uterine smooth muscle under the spasticity and suppress the contraction of uterine smooth muscle.
Table 10 pair isolated uterine smooth muscle influence n:8 x ± SD
(annotate: ↓ expression reduces, and ↑ expression increases;
*For administration self cross-reference compares,
*P＜0.05,
*P＜0.01, # compares #P＜0.05, ##P＜0.01 with matched group)
Embodiment 1:
Radix Angelicae Sinensis 70kg Rhizoma Chuanxiong 32kg Semen Persicae 20kg
Flos Carthami 20kg Cortex Moutan 30kg Radix Salviae Miltiorrhizae 38kg
Radix Rehmanniae Preparata 85kg Radix Bupleuri 25kg Radix Paeoniae Alba 18kg
Rhizoma Cyperi (processed) 25kg Radix Curcumae 20kg Radix Achyranthis Bidentatae 28kg
Radix Polygoni Multiflori Preparata 95kg
With common the decoction 2 times of above 13 flavors, adding 4 times of water gagings the 1st time boiled 2 hours, adding 2 times of water gagings the 2nd time boiled 1.5 hours, boil and collect Aromatic water simultaneously, merging decocting liquid twice, leave standstill, is centrifugal under 7320r/min, the current-carrying capacity 300L/hr condition at rotating speed, at pressure is that 0.07MP, temperature are to concentrate under 60～70 ℃ of conditions, relative density greater than 1.07 concentrated solution; With 14% refined honey, Aromatic water, concentrated solution dosing together, relative density is reached more than 1.07, regulate pH to 7.3～7.5 with NaOH, HCl weak solution; Left standstill below 5 ℃ 24 hours; Ultrafiltration under pressure 0.15Mpa condition, ultrafiltration molecular weight≤35000 of damming, the filtrate packing, 1ml/ props up, and every contains suitable crude drug amount is 5.06g.
Claims (10)
1, a kind of Chinese medicine composition with treatment dysmenorrhea effect and beautification function is characterized in that said composition made by following raw medicaments in portion by weight:
Radix Angelicae Sinensis 35-105 Rhizoma Chuanxiong 16-48 Semen Persicae 10-30 Flos Carthami 10-30
Cortex Moutan 15-45 Radix Salviae Miltiorrhizae 19-57 Radix Rehmanniae Preparata 40-120.
2, Chinese medicine composition as claimed in claim 1 is characterized in that said composition made by following raw medicaments in portion by weight:
Radix Angelicae Sinensis 63-77 Rhizoma Chuanxiong 29-33 Semen Persicae 18-22 Flos Carthami 18-22
Cortex Moutan 27-33 Radix Salviae Miltiorrhizae 34-42 Radix Rehmanniae Preparata 77-93.
3, Chinese medicine composition as claimed in claim 1 is characterized in that said composition made by following raw medicaments in portion by weight:
Radix Angelicae Sinensis 70 Rhizoma Chuanxiongs 32 Semen Persicaes 20 Flos Carthamis 20
Cortex Moutan 30 Radix Salviae Miltiorrhizaes 38 Radix Rehmanniae Preparata 85.
4, Chinese medicine composition as claimed in claim 1, the raw material that it is characterized in that preparing said composition adds the component of following weight parts again:
Radix Bupleuri 13-38 Radix Paeoniae Alba 9-27 Rhizoma Cyperi (processed) 13-38
Radix Curcumae 10-30 Radix Achyranthis Bidentatae 14-42 Radix Polygoni Multiflori Preparata 50-150.
5, Chinese medicine composition as claimed in claim 2 is characterized in that preparing the component that adds following weight parts in the raw material of said composition:
Radix Bupleuri 23-28 Radix Paeoniae Alba 16-20 Rhizoma Cyperi (processed) 23-28
Radix Curcumae 18-22 Radix Achyranthis Bidentatae 25-31 Radix Polygoni Multiflori Preparata 86-104.
6, Chinese medicine composition as claimed in claim 3 is characterized in that preparing the component that adds following weight parts in the raw material of said composition:
Radix Bupleuri 25 Radix Paeoniae Albas 18 Rhizoma Cyperi (processed) 25
Radix Curcumae 20 Radix Achyranthis Bidentataes 28 Radix Polygoni Multiflori Preparata 95.
7,, it is characterized in that this method is as the preparation method of claim 4,5 or 6 described Chinese medicine compositions:
The flavor medicines are common decocts 2 times with 13, add 3-6 times of water gaging the 1st time to boil 1-3 hour, and adding 1-3 times of water gaging the 2nd time boiled 1-2 hour, boiled and collected Aromatic water simultaneously, merged decocting liquid twice, left standstill, centrifugal, concentrate, relative density greater than 1.07 concentrated solution; The dosing together of Aromatic water, concentrated solution, dosing is left standstill, ultrafiltration or continue to concentrate, drying, any clinical acceptable forms is made in packing.
8,, it is characterized in that this preparation method is as the preparation method of claim 4,5 or 6 described Chinese medicine compositions:
The flavor medicines are common decocts 2 times with 13, add 3-6 times of water gaging the 1st time to boil 1-3 hour, and adding 1-3 times of water gaging the 2nd time boiled 1-2 hour, boiled and collected Aromatic water simultaneously, merged decocting liquid twice, left standstill, centrifugal, concentrate, relative density greater than 1.07 concentrated solution; With 14% refined honey, Aromatic water, concentrated solution dosing together, relative density is reached more than 1.07, regulate pH to 7.3～7.5 with NaOH, HCl weak solution; Left standstill 24 hours; Ultrafiltration, packing, 10ml/ props up, and every contains suitable crude drug amount is 5.06g.
9, the preparation method of Chinese medicine composition as claimed in claim 8 is characterized in that this preparation method is:
With common the decoction 2 times of above 13 flavors, adding 4 times of water gagings the 1st time boiled 2 hours, adding 2 times of water gagings the 2nd time boiled 1.5 hours, boil and collect Aromatic water simultaneously, merging decocting liquid twice, leave standstill, is centrifugal under 7320r/min, the current-carrying capacity 300L/hr condition at rotating speed, at pressure is that 0.07MP, temperature are to concentrate under 60～70 ℃ of conditions, relative density greater than 1.07 concentrated solution; With 14% refined honey, Aromatic water, concentrated solution dosing together, relative density is reached more than 1.07, regulate pH to 7.3～7.5 with NaOH, HCl weak solution; Left standstill below 5 ℃ 24 hours; Ultrafiltration under pressure 0.15Mpa condition, ultrafiltration molecular weight≤35000 of damming, the filtrate packing, 10ml/ props up, and every contains suitable crude drug amount is 5.06g.
10, as claim 1,2,3,4, the application of 5 or 6 described compositionss in the medicine of preparation treatment menoxenia, dysmenorrhea, chloasma, senile plaque, wrinkle of skin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021165734A CN1209128C (en) | 2002-04-09 | 2002-04-09 | Traditional Chinese medicine composition with function of treating dysmenorrhea and beautifying |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021165734A CN1209128C (en) | 2002-04-09 | 2002-04-09 | Traditional Chinese medicine composition with function of treating dysmenorrhea and beautifying |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1449778A CN1449778A (en) | 2003-10-22 |
| CN1209128C true CN1209128C (en) | 2005-07-06 |
Family
ID=28680775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021165734A Expired - Lifetime CN1209128C (en) | 2002-04-09 | 2002-04-09 | Traditional Chinese medicine composition with function of treating dysmenorrhea and beautifying |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1209128C (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1751676B (en) * | 2004-09-22 | 2010-04-28 | 天津天士力制药股份有限公司 | Diaphragm ultrafiltration method for refining traditional Chinese medicine |
| CN101066080B (en) * | 2007-05-28 | 2010-05-19 | 吴建生 | Lady's beauty tea |
| CN101366880B (en) * | 2008-09-11 | 2011-05-04 | 刘运波 | Traditional Chinese medicine for treating menorrhalgia |
| CN101715960B (en) * | 2008-12-02 | 2013-10-02 | 天津天狮生物发展有限公司 | Beauty capsule and production and manufacturing process thereof |
| CN101637554B (en) * | 2009-09-01 | 2011-08-10 | 赵玉英 | Orally taken Chinese medicine for curing freckle and chloasma and preparation method thereof |
| CN102178631B (en) * | 2011-05-04 | 2012-09-26 | 北京华夏美枫化妆品技术中心 | Skin care combination with effect of dispelling wrinkles, preparation and preparation method |
| CN102526635B (en) * | 2012-03-06 | 2013-06-05 | 钟美琴 | Medicament for treating premenstrual stress syndrome and preparation method thereof |
| CN103142722B (en) * | 2013-03-13 | 2014-04-02 | 辛秀芳 | Traditional Chinese medicine composition for treating liver qi depression type irregular menstruation |
| CN104147508A (en) * | 2014-07-18 | 2014-11-19 | 甘保明 | Traditional Chinese medicine composition for treating irregular menstruation |
| CN104324075A (en) * | 2014-09-30 | 2015-02-04 | 苏州市天灵中药饮片有限公司 | Traditional Chinese medicine capsule for treating dysmenorrhea and preparation method thereof |
| CN104958711A (en) * | 2015-07-29 | 2015-10-07 | 青岛蓝盛洋医药生物科技有限责任公司 | Pharmaceutical composition for treating chloasma and preparation method thereof |
| CN105012878A (en) * | 2015-07-30 | 2015-11-04 | 王华荣 | Traditional Chinese medicine composition for treating dysmenorrhea |
| CN105168789A (en) * | 2015-10-20 | 2015-12-23 | 黄秋丽 | Traditional Chinese medicine composition for conditioning irregular menstruation and preparation method of traditional Chinese medicine composition |
| CN105267543A (en) * | 2015-11-23 | 2016-01-27 | 青岛麦瑞特医药技术有限公司 | Chinese medical preparation for treating qi-stagnation and blood stasis type primary dysmenorrheal and chloasma |
| CN106729203A (en) * | 2016-12-16 | 2017-05-31 | 金乡县金醫堂保健食品有限公司 | A kind of Chinese medicine for treating Hypomenorrhea |
| CN107951951B (en) * | 2018-01-25 | 2021-04-13 | 向昌荣 | Traditional Chinese medicine composition for removing senile plaques and preparation method thereof |
| CN116327879A (en) * | 2023-02-07 | 2023-06-27 | 深圳太太药业有限公司 | Traditional Chinese medicine composition for conditioning dysmenorrhea and maintaining beauty and keeping young and product and preparation method thereof |
-
2002
- 2002-04-09 CN CNB021165734A patent/CN1209128C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1449778A (en) | 2003-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1209128C (en) | Traditional Chinese medicine composition with function of treating dysmenorrhea and beautifying | |
| CN1245952C (en) | Depigmenting cosmetic skin-care composition and use thereof | |
| CN101032560A (en) | Chinese medicine composition for treating somnipathy and preparing method thereof | |
| CN1840166A (en) | Modern Chinese medicinal oral liquid of 'Wen Dan Tang' and preparation method thereof | |
| CN1233387C (en) | Chinese compound medicine for treating anhypnosis and its preparation metod | |
| CN1228074C (en) | Chinese traditional medicine for treating immune hypofunction and disfunction | |
| CN1285358C (en) | Medicinal composition, preparation and quality control thereof | |
| CN1698878A (en) | Kidney replenishing medicinal composition and its preparation process and novel use | |
| CN1255154C (en) | Deer's fetus granular Chinese madicinal preparation and its production technology | |
| CN1927331A (en) | Chinese medicine preparation for curing chronic heart failure | |
| CN1739743A (en) | Medicine for treating parkinson's disease and Parkinson's syndrome and its prepn | |
| CN100344304C (en) | Chinese medicinal preparation for treating consumptive disease and its making method thereof | |
| CN1706435A (en) | Chinese medicine composition for treating premenstrual stage stress syndrome an dits prepn process | |
| CN101036722A (en) | Health-caring food for easing and improving climacteric Syndrome of men and the preparation thereof | |
| CN100344315C (en) | Medicinal composition for promoting bone fracture healing and its preparing method | |
| CN1232267C (en) | Compound plant medicine and its application | |
| CN1820770A (en) | Chinese medicine composition for treating apoplexy and its preparing method | |
| CN1292786C (en) | Method for preparing Chinese medicine composition for treating ischemic brain apoplexy | |
| CN1335161A (en) | Deer bone powder capsule | |
| CN1290566C (en) | Depression treating medicinal formulation and its preparation process | |
| CN1990022A (en) | Traditional Chinese medicine composition, its preparation and quality controlling means | |
| CN1222305C (en) | Chinese medicine for treating liver-kidney insufficiency, qi and yin vacuity and its preparation method | |
| CN1650895A (en) | Method of extracting medicamout having memory strengthening function from natural plant compound preparation | |
| CN1290547C (en) | Traditional Chinese medicine for treating and preventing high blood pressure and its preparation technology | |
| CN1277574C (en) | Beautifying and climacteric syndrome treating composition, its preparing process and usage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20050706 |